The Chinese Pharmaceutical market is currently the second greatest pharma market globally, in 2014 was worth $105 billion. It is forecast to increase dramatically to $200 billion by 2020 and increase its dominance as a leading player in Asia.
It is paramount for Governments to tackle not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete are analysed into key drivers, constraints, challenges and opportunities for future growth and development
The launch of PharmaCon China, 28 – 31 March 2016 is therefore timely and will co-locate Clinical Trials China, Pharma Regulatory Summit China and Pharma Compliance China to cover in-depth the issues that are affecting the drug development and research landscape!
Key Speakers Included:
Dr Meir-Chyun Tzou